Moderna: Use ChatGPT 20 Times a Day
Moderna is taking major steps forward in its collaboration with OpenAI and setting ambitious goals for the use of ChatGPT in its operations. CEO Stéphane Bancel is driving a revolution in the pharmaceutical industry with the help of AI.
Moderna, known for its groundbreaking mRNA vaccine against COVID-19, has entered into a partnership with OpenAI, the organization behind the innovative chatbot ChatGPT. This partnership is intended to integrate artificial intelligence more deeply into the company's core operations, such as research, legal, and manufacturing, through the use of ChatGPT Enterprise.
Stéphane Bancel: "Use ChatGPT 20 Times a Day"
According to an interview with The Wall Street Journal, reported by Gizmodo, Moderna CEO Stéphane Bancel has a vision of intensifying the use of ChatGPT within the company. Bancel, who has been fascinated by the tool since its launch in late 2022, is setting an ambitious goal for his employees to use the chatbot at least 20 times a day. He believes this tool will not only boost efficiency but also play a critical role in how work gets done at Moderna.
AI's Role in Moderna's Vision for the Future
It's clear that Moderna's leadership sees great potential in AI technology's ability to radically transform the pharmaceutical industry. The Wall Street Journal highlights that, with the help of AI, the company aims to exceed its own targets by launching 15 new products over the next five years. Bancel compares AI's impact to how personal computers revolutionized work and personal life in the 1980s, and sees OpenAI as a leading force in this transformation.
Conclusion and Future Outlook
With this partnership, Moderna is putting itself at the forefront of exploring and implementing AI solutions in the pharmaceutical industry. Embracing such technologies signals a significant shift in how traditional processes and workflows may be transformed and streamlined.